Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

What are the most concerning side effects of Ozempic and other weight-loss drugs? - Gastrointestinal and cardiovascular ...

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLernTM ... its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

Prescription weight loss medications, including GLP-1 agonists, orlistat ... is in a class of medications known as melanocortin 4 (MC4) receptor agonists. It’s an injectable medication approved ...

Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...

This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ... new chemotype with an entirely unique binding mode. Biolexis is actively completing ...